Loading...
Loading...
APRE| Name | Value |
|---|---|
| Revenues | 118.1K |
| Cost of Revenue | 5.4K |
| Gross Profit | 112.7K |
| Operating Expense | 3,505.9K |
| Operating I/L | -3,387.8K |
| Other Income/Expense | 148.9K |
| Interest Income | 178.0K |
| Pretax | -3,238.9K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -3,238.9K |
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing cancer therapeutics targeting DNA damage response pathways. Their lead product candidate, ATRN-119, is an oral ATR inhibitor currently in phase 1/2a clinical trial for advanced solid tumors. The company's product pipeline also includes ATRN-Backup, ATRN-W1051, and ATRN-DDRi, all aimed at treating anti-tumor activity. Aprea Therapeutics, Inc. generates revenue through the development and potential commercialization of these novel cancer therapeutics.
